PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.79%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-30.79%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-31.28%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-21.00%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-22.22%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
7.78%
Share count expansion well above AXSM's 1.90%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.68%
Diluted share count expanding well above AXSM's 1.90%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-4.39%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-4.24%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7210.53%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
76.96%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
70.68%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
-11609.25%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
81.05%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
70.82%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
881.79%
Equity/share CAGR of 881.79% while AXSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-26.92%
Negative 5Y equity/share growth while AXSM is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-79.64%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.21%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-41.29%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-11.75%
We’re deleveraging while AXSM stands at 0.90%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
20.45%
R&D dropping or stable vs. AXSM's 43.92%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
69.30%
SG&A growth well above AXSM's 27.26%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.